These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36539621)

  • 21. [Which animal models of nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) have more practical value in experimental investigations?].
    Duan NN; Wu J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):230-3. PubMed ID: 27095770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
    Agosti P; Sabbà C; Mazzocca A
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons from mouse models of high-fat diet-induced NAFLD.
    Nakamura A; Terauchi Y
    Int J Mol Sci; 2013 Oct; 14(11):21240-57. PubMed ID: 24284392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical models of non-alcoholic fatty liver disease.
    Santhekadur PK; Kumar DP; Sanyal AJ
    J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis.
    Zarrouki B; Boucher J
    Methods Mol Biol; 2020; 2164():121-127. PubMed ID: 32607889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
    Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
    J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present.
    Jacobs A; Warda AS; Verbeek J; Cassiman D; Spincemaille P
    Curr Protoc Mouse Biol; 2016 Jun; 6(2):185-200. PubMed ID: 27248434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
    Koo SY; Park EJ; Lee CW
    Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
    Heredia JE; Sorenson C; Flanagan S; Nunez V; Jones C; Martzall A; Leong L; Martinez AP; Scherl A; Brightbill HD; Ghilardi N; Ding N
    PLoS One; 2022; 17(9):e0274582. PubMed ID: 36107926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
    Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
    J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.
    Chen K; Ma J; Jia X; Ai W; Ma Z; Pan Q
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):117-125. PubMed ID: 30528647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells.
    Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R
    Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.